Oncolys BioPharma Inc.

TSE:4588.T

571 (JPY) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q32015 Q22015 Q12014 Q42014 Q32014 Q22014 Q12013 Q4
Revenue 31.38400028.03835191.673358.357233.027193.125324.177125.25130.46462.603106.56871.49665.84170.274663.73319.105572.62348.38350.12727.97756.57133.874200.1129.1234.52415.38131.7731.8615.1229.56101.36812.0265.7632.14621.6712.9231.8632.341.14
Cost of Revenue 001.6060.5390.14132.433163.338287.66121.05665.641294.75495.4218.08935.4273.75639.64815.15519.50653.7898.2779.29941.53531.919.42241.48628.52367.5893.9610.00700.008000.00800.0010.0030.0130.3290.0210.0060.0380.029
Gross Profit 31.3840-1.606-0.53927.8972.56728.33570.697111.971127.48429.42329.83112.37527.176102.81231.84850.68650.768609.94410.828563.3246.84818.2278.55515.0855.351132.5235.1624.51715.38131.7651.8615.1229.552101.36812.0255.762.13321.3422.9021.8572.3021.111
Gross Profit Ratio 10000.9950.0730.1480.1970.4810.660.0910.2380.8610.4340.9650.4450.770.7220.9190.5670.9840.1420.3640.3060.2670.1580.6620.5660.99811111110.9990.9940.9850.9930.9970.9840.975
Reseach & Development Expenses 301.833222.142454.603260.385457.795179.157160.411201.815237.431347.834334.109170.071214.666106.628340.212647.0300153.509409.18500195.749410.0720000000000000000000
General & Administrative Expenses 0000000000000000000000000000000000000000000
Selling & Marketing Expenses 0000000000000000000000000000000000000000000
SG&A 144.05156.73162.739149.125145.513148.988135.049147.365148.691164.397186.219189.808181.855270.001617.516539.35429.341338.458576.526322.595473.963371.43350.382280.241356.143308.015442.495263.916279.064250.4950000000000000
Other Expenses -144.05002.7590328.145295.46349.18386.122512.231-40-0.887-12.912-14.168-17.2-0.287-6.055-0.03-32.103-9.8650.0270.05350.382280.241356.1430.03442.495263.916279.0640.029-0.7980.810.2660.025-0.373205.4240.51198.8710.4580.49319.10567.9942.187
Operating Expenses 445.883378.872617.342410.049603.449328.145295.46349.18386.122512.231520.328359.879396.521376.629609.959539.063423.286338.458534.418322.595473.963371.43350.382280.241356.143308.015442.495263.916279.064250.495313.519270.82243.655211.614354.171205.424206.928306.339325.867167.832191.551170.898258.789
Operating Income -414.499-378.872-618.948-410.049-575.411-325.578-267.125-278.483-274.151-384.748-490.905-330.05-284.146-349.453-507.148-507.214-372.6-287.6975.525-311.76789.361-364.582-332.155-271.686-341.058-302.664-309.973-258.754-274.547-235.115-181.755-268.96-228.535-182.061-252.803-193.398-201.168-304.206-304.524-164.929-189.694-168.597-257.678
Operating Income Ratio -13.207000-20.523-9.302-1.394-0.777-1.176-1.992-1.514-2.635-2.178-5.582-4.759-7.094-5.659-4.0940.114-16.3190.156-7.535-6.626-9.711-6.029-8.935-1.549-28.363-60.687-15.287-1.379-144.602-15.115-6.159-2.494-16.082-34.907-141.755-14.052-56.425-101.822-72.05-226.033
Total Other Income Expenses Net 24.79415.58-45.9816.70531.0612.623-45.83114.54233.26556.526-143.9182.174-15.244-0.172-41.592-372.514-5.2312.631-396.314-4.408-1.7715.3631.212.5311.503-7.774-0.431-0.99-0.912-6.463-16.695-43.965-2.89-3.483-2.734-0.506-0.02100.13511.9755.7599.10163.804-35.426
Income Before Tax -389.705-363.292-664.929-403.344-544.35-322.955-312.956-263.941-240.886-328.222-634.823-327.876-299.389-349.626-548.74-879.728-377.832-285.059-320.788-316.17687.591-359.22-330.955-259.156-329.555-310.439-310.403-259.744-275.46-241.578-198.449-312.925-231.425-185.545-255.537-193.905-201.187-204.072-292.549-159.171-180.593-104.793-293.104
Income Before Tax Ratio -12.417000-19.415-9.227-1.633-0.737-1.034-1.7-1.958-2.618-2.295-5.585-5.149-12.305-5.739-4.056-0.483-16.5490.153-7.425-6.602-9.263-5.826-9.165-1.551-28.471-60.889-15.707-1.506-168.239-15.306-6.277-2.521-16.124-34.91-95.094-13.5-54.455-96.937-44.783-257.109
Income Tax Expense 0.9310.940.7330.7360.7210.7360.7330.7380.7230.7380.9380.9430.9030.9410.9380.9460.8810.9620.9390.9650.8830.9650.9390.9730.8820.9460.940.9550.6540.9691.3980.6550.3170.6820.6290.7220.6360.601-0.4321.0450.6220.6570.821
Net Income -390.635-364.233-665.662-404.081-545.071-323.691-313.689-264.679-241.609-328.96-635.76-328.819-300.293-350.567-549.679-880.674-378.712-286.022-321.727-317.14186.707-360.185-331.895-260.129-330.436-311.386-311.342-260.699-276.115-242.547-199.847-313.581-231.741-186.228-256.166-194.628-201.822-204.674-292.118-160.216-181.215-105.45-293.925
Net Income Ratio -12.447000-19.44-9.248-1.637-0.739-1.037-1.703-1.961-2.625-2.302-5.6-5.158-12.318-5.752-4.07-0.485-16.60.151-7.444-6.621-9.298-5.841-9.192-1.556-28.576-61.033-15.77-1.517-168.592-15.327-6.3-2.527-16.184-35.02-95.375-13.48-54.812-97.271-45.064-257.829
EPS -18.73-18.24-35.09-23.02-31.47-18.69-18.11-2.46-2.25-18.98-6.04-20.97-19.15-22.36-35.06-56.17-26.48-19.96-22.64-22.316.48-26.91-25.36-23.46-29.81-28.09-28.25-27.85-29.49-25.91-21.66-34.15-25.23-20.28-27.89-21.19-21.98-22.29-31.81-17.51-19.81-11.53-32.13
EPS Diluted -18.73-18.24-35.09-23.02-31.47-18.69-18.11-2.46-2.25-18.98-5.91-20.97-19.15-22.36-35.06-56.17-26.43-19.96-22.45-22.136.48-26.91-24.79-19.43-29.81-28.09-28.08-23.52-29.49-25.91-21.35-33.49-25.23-20.28-27.89-21.19-21.98-22.29-31.81-17.45-19.81-11.53-32.13
EBITDA -414.499-378.872-617.342-402.346-543.424-322.236-307.621-262.865-239.813-348.764-633.845-326.794-298.212-348.694-536.563-878.596-376.607-284.283-319.662-315.12588.772-358.631-330.317-258.477-328.837-309.677-309.583-258.886-274.559-240.883-171.88-269.014-230.591-184.677-254.609-192.925-200.178-202.745-288.487-157.929-179.652-103.41-292.176
EBITDA Ratio -13.207000-19.382-9.207-1.605-0.734-1.029-1.806-1.955-2.609-2.286-5.57-5.035-12.289-5.72-4.045-0.482-16.4940.155-7.412-6.59-9.239-5.813-9.142-1.547-28.377-60.689-15.662-1.304-144.631-15.251-6.248-2.512-16.042-34.735-94.476-13.312-54.03-96.432-44.192-256.295